Angelini Pharma Collaborated with JCR Pharmaceuticals to Develop and Commercialize Novel Biologic Therapies for Epilepsy
Shots:
- JCR will receive reimbursement of research expenses and an up front & will also be eligible to receive additional fees of ~$505.5M upon achievement of development & commercial milestones along with royalties on post-approval net sales
- Following the pre-clinical development phase, Angelini Pharma will have an exclusive license for the clinical development of therapeutic candidates & their commercialization outside of Japan. JCR retains the right to commercialize the drug in Japan
- The agreement will combine Angelini Pharma’s expertise in neurological diseases with JCR blood-brain barrier technology, J-Brain Cargo for the identification of brain-penetrant biologic therapies to treat epilepsy patients
Ref: Angelini Pharma | Image: Angelini Pharma
Related News:- JCR Pharmaceuticals’ JR-141 Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Mucopolysaccharidosis Type II
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
